10-Q - Beam Therapeutics Inc. (0001745999) (Filer)

8-K - Beam Therapeutics Inc. (0001745999) (Filer)

DEFA14A - Beam Therapeutics Inc. (0001745999) (Filer)

DEF 14A - Beam Therapeutics Inc. (0001745999) (Filer)

SCHEDULE 13G/A - Beam Therapeutics Inc. (0001745999) (Subject)

424B5 - Beam Therapeutics Inc. (0001745999) (Filer)

8-K - Beam Therapeutics Inc. (0001745999) (Filer)

FWP - Beam Therapeutics Inc. (0001745999) (Subject)

424B5 - Beam Therapeutics Inc. (0001745999) (Filer)

8-K - Beam Therapeutics Inc. (0001745999) (Filer)

BofA Securities upgraded Beam Therapeutics from Neutral to Buy and set a new price target of $42.00

Scotiabank upgraded Beam Therapeutics from Sector Perform to Sector Outperform and set a new price target of $40.00

Cantor Fitzgerald upgraded Beam Therapeutics from Neutral to Overweight

Leerink Partners upgraded Beam Therapeutics from Market Perform to Outperform and set a new price target of $39.00 from $27.00 previously

Scotiabank initiated coverage of Beam Therapeutics with a rating of Sector Outperform

H.C. Wainwright initiated coverage of Beam Therapeutics with a rating of Buy and set a new price target of $80.00

JP Morgan upgraded Beam Therapeutics from Neutral to Overweight and set a new price target of $40.00 from $38.00 previously

BofA Securities downgraded Beam Therapeutics from Buy to Neutral and set a new price target of $35.00

Jefferies downgraded Beam Therapeutics from Buy to Hold and set a new price target of $30.00 from $75.00 previously

Cantor Fitzgerald downgraded Beam Therapeutics from Overweight to Neutral

First Patient Dosed in the Phase 1/2 Study of BEAM-301 in Glycogen Storage Disease Type Ia, Beam's Second Clinical Stage In Vivo Editing Program Updated Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 Accepted for Presentation at the European Hematology Association 2025 Congress in June Following Positive Initial Data for BEAM-302 in Alpha-1 Antitrypsin Deficiency, Company Initiated Dosing of Fourth Cohort in Part A of Phase 1/2 Trial and Received Clearance of U.S. IND; Updated Data Expected to be Presented in Second Half of 2025 Ended First Quarter 2025 with $1.2 Billion in Cash, Cash Equivalents and Marketable Securities, Including Net Proceeds from $500 Million Financing; Cash Ru

New Data Demonstrate Proportion of Corrected M-AAT Reached a Mean of 91% of Total AAT in Circulation at Day 28 Following BEAM-302 Treatment in 60 mg Cohort (n=3) Mean Decrease of 79% in Mutant Z-AAT Observed at Day 28 in 60 mg Cohort (n=3) Fourth Cohort Evaluating 75 mg of BEAM-302 Initiated, with Updated Data from Part A of the Phase 1/2 Trial Expected to be Presented at a Medical Conference in Second Half of 2025 CAMBRIDGE, Mass., April 05, 2025 (GLOBE NEWSWIRE) --  Beam Therapeutics Inc. (NASDAQ:BEAM), a biotechnology company developing precision genetic medicines through base editing, today presented additional data from the Phase 1/2 clinical trial of BEAM-302 in patients with alph

U.S. IND Represents Regulatory Clearance For BEAM-302 Spanning Six Countries and Second Open IND for a Beam In Vivo Base Editing Program in the U.S. CAMBRIDGE, Mass., March 27, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (NASDAQ:BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that the United States (U.S.) Food and Drug Administration (FDA) has cleared the investigational new drug (IND) application for BEAM-302 for the treatment of alpha-1 antitrypsin deficiency (AATD). AATD is an inherited genetic disorder that affects the lungs and/or liver, leading to early onset emphysema and liver disease, and for which there are no curre

CAMBRIDGE, Mass., March 10, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (NASDAQ:BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the pricing of an underwritten offering of 16,151,686 shares of its common stock at an offering price of $28.48 per share, and, in lieu of common stock to certain investors, pre-funded warrants to purchase 1,404,988 shares of common stock at an offering price of $28.47 per pre-funded warrant, before deducting underwriter discounts and commissions and estimated offering expenses. Each pre-funded warrant will have an exercise price of $0.01 per share, will be exercisable immediately and will be exercisa

Single Dose of BEAM-302 Led to Durable, Dose-dependent Increases in Total and Functional Alpha-1 Antitrypsin (AAT), Production of Corrected M-AAT, and Decreases in Mutant Z-AAT in Circulation Across Initial Three Dose Levels Third Dose Level of BEAM-302 (60 mg, N=3) Achieved Mean Total AAT of 12.4µM at Day 28, Exceeding Protective Therapeutic Threshold, and Reduced Mutant Z-AAT up to 78% Initial Safety Findings Demonstrated BEAM-302 was Well Tolerated at All Dose Levels with No Serious Adverse Events or Dose-Limiting Toxicities Observed Clinical Profile Supports Continued Dose Escalation, with Updated Data from Part A of the Phase 1/2 Trial Expected to be Presented at Medical Conference

Enrollment Target for Adult Sickle Cell Disease Patients Achieved in BEACON Trial ofBEAM-101; Dosing of 30 Patients and Updated Data Expected by Mid-2025 Initial Data from Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency Expected in First Half 2025 Dosing Expected to Initiate in Phase 1/2 Trial of BEAM-301 in Glycogen Storage Disease Type 1a in Early 2025 IND-enabling Studies of ESCAPE Nongenotoxic Conditioning Approach Ongoing; Healthy Volunteer Study of BEAM-103 Antibody Expected to Initiate by Year-end Ended Fourth Quarter 2024 with $850.7 Million in Cash, Cash Equivalents and Marketable Securities; Cash Runway Expected to Support Operating Plans i

CAMBRIDGE, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (NASDAQ:BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that management will participate in fireside chats at the following upcoming investor conferences: TD Cowen 45th Annual Health Care Conference on Monday, March 3, 2025, at 1:50 p.m. ETLeerink Partners Global Biopharma Conference on Monday, March 10, 2025, at 1:40 p.m. ETBarclays Global Healthcare Conference on Tuesday, March 11, 2025, at 3:30 p.m. ET The live webcasts will be available in the investor section of the company's website at www.beamtx.com and will be archived for 60 days following th

CAMBRIDGE, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (NASDAQ:BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that John Evans, chief executive officer of Beam, plans to participate in a fireside chat during the Guggenheim SMID Cap Biotech Conference on Thursday, February 6, 2025, at 2:30 p.m. ET in New York. A live webcast will be available in the investor section of the company's website at www.beamtx.com and will be archived for 60 days following the presentation. About Beam TherapeuticsBeam Therapeutics (NASDAQ:BEAM) is a biotechnology company committed to establishing the leading, fully integrated platfo

CAMBRIDGE, Mass., Jan. 23, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (NASDAQ:BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the company will encore data from the BEACON Phase 1/2 clinical trial of BEAM-101 in sickle cell disease in an oral presentation at the 2025 Tandem Meetings | Transplantation & Cellular Therapy Meetings of the American Society for Transplantation and Cellular Therapy (ASTCT) and Center for International Blood and Marrow Transplant Research (CIBMTR) taking place February 12 – 15, 2025, in Honolulu, Hawaii.  Data from seven patients treated with investigational base-editing therapy BEAM-101 were previou

More Than 40 Adult Sickle Cell Disease Patients Now Enrolled in BEACON Trial of BEAM-101; Beam Expects to Dose 30 Patients and Present Updated Data by Mid-2025 Initial Data from Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency Expected in First Half 2025 Dosing Anticipated to Commence in Phase 1/2 Trial of BEAM-301 in Glycogen Storage Disease Type 1a in Early 2025 IND-enabling Studies of ESCAPE Nongenotoxic Conditioning Approach Underway, with Healthy Volunteer Study of BEAM-103 Antibody Expected to Initiate by Year-end Cash Runway Expected to Support Operating Plans into 2027, Now Inclusive of Commercial Readiness Activities for BEAM-101 Cambridge, Mass., Jan. 13, 2025 (

Single Dose of BEAM-302 Led to Durable, Dose-dependent Increases in Total and Functional Alpha-1 Antitrypsin (AAT), Production of Corrected M-AAT, and Decreases in Mutant Z-AAT in Circulation Across Initial Three Dose Levels Third Dose Level of BEAM-302 (60 mg, N=3) Achieved Mean Total AAT of 12.4µM at Day 28, Exceeding Protective Therapeutic Threshold, and Reduced Mutant Z-AAT up to 78% Initial Safety Findings Demonstrated BEAM-302 was Well Tolerated at All Dose Levels with No Serious Adverse Events or Dose-Limiting Toxicities Observed Clinical Profile Supports Continued Dose Escalation, with Updated Data from Part A of the Phase 1/2 Trial Expected to be Presented at Medical Conference

Initial Clinical Data for BEAM-101 and Preclinical Non-human Primate Data for ESCAPE Accepted for Presentation at American Society of Hematology (ASH) Annual Meeting 35 Patients Enrolled and Eight Patients Dosed in BEACON Phase 1/2 Trial of BEAM-101 in Sickle Cell Disease First Cohort Dosing Completed in Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency; Initial Clinical Data Expected in 2025 Ended Third Quarter 2024 with $925.8 Million in Cash, Cash Equivalents and Marketable Securities; Expected Operating Runway into 2027 Company to Host Conference Call Today, November 5, 2024, at 8:30 a.m. ET CAMBRIDGE, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (NA

CAMBRIDGE, Mass., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (NASDAQ:BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the company will host a conference call and webcast on Tuesday, November 5, 2024, at 8:30 a.m. ET to discuss its third quarter 2024 financial results and review the company's abstracts accepted for presentation at the upcoming 66th Annual Meeting of the American Society for Hematology (ASH). A live webcast of the presentation will be available here and under "Events & Presentations" in the Investors section of the company's website at www.beamtx.com. A replay of the webcast will be archived on the com

Recent Portfolio Prioritization Focuses Business on Key Near-term Value Drivers and Long-term Growth of Precision Genetic Medicines Pipeline Lilly Acquires Beam's Opt-In Rights to Verve Therapeutics' Base Editing Cardiovascular Programs for up to $600 Million in Combined Upfront Payment, Equity Investment and Potential Future Development-Stage Payments GMP Operations Initiated at Beam's North Carolina Manufacturing Facility Strong Balance Sheet Provides Anticipated Operating Runway into the Second Half of 2026 CAMBRIDGE, Mass., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (NASDAQ:BEAM), a biotechnology company developing precision genetic medicines through base editing, to

Research Collaboration with Pfizer Underway, with Upfront and Potential Milestone Payments of Up to $1.35 Billion Executing First Wave of Long-term Strategy for Sickle Cell Disease with Planned Initiation of BEAM-101 Clinical Trial and IND Submission for BEAM-102 in the Second Half of 2022 Strong Cash Position of $1.2 Billion, Including Pfizer Upfront, to Support Robust Set of Milestones Across Ex Vivo and In Vivo Base Editing Programs Anticipated in 2022 and Beyond CAMBRIDGE, Mass., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (NASDAQ:BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced pipeline and business highlights,

BEAM-101 IND Cleared by FDA for Evaluation as a Treatment for Sickle Cell Disease BEAM-102 IND-Enabling Studies Also Underway CAMBRIDGE, Mass., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (NASDAQ:BEAM), a biotechnology company developing precision genetic medicines through base editing, today reported recent business and pipeline updates, as well as third quarter 2021 financial results. As part of today's update, Beam announced that its Investigational New Drug (IND) application for BEAM-101 for the treatment of sickle cell disease was cleared by the U.S. Food and Drug Administration (FDA). BEAM-101, the company's lead ex vivo base editing product candidate, is a patient-sp

Company On-track to Submit First IND for BEAM-101 in the Second Half of 2021 Continued Progress Across Base Editing Portfolio, Including Initiation of IND-Enabling Studies for BEAM-201 CAMBRIDGE, Mass., Aug. 10, 2021 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (NASDAQ:BEAM), a biotechnology company developing precision genetic medicines through base editing, today reported recent business and pipeline updates, as well as second quarter 2021 financial results. "We have made meaningful progress in advancing our base editing programs in the first half of the year, and importantly, remain on track to submit our first investigational new drug (IND) for BEAM-101 in the second half of this year

Data from Beam's Novel LNP-mRNA Formulation Demonstrates In Vivo Editing in Liver Cells of Non-human Primates Up to 52% Company On-track to Submit First IND for BEAM-101 in the Second Half of 2021 CAMBRIDGE, Mass., May 11, 2021 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (NASDAQ:BEAM), a biotechnology company developing precision genetic medicines through base editing, today reported recent business highlights and pipeline updates, as well as first quarter 2021 financial results. "As Beam prepares to enter the clinic, we also continue to extend our leadership position in the field of base editing by expanding our platform and delivery capabilities," said John Evans, chief executive offic

CAMBRIDGE, Mass., Feb. 23, 2021 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced it has completed the acquisition of Guide Therapeutics, Inc. (“GuideTx”), a developer of nonviral drug delivery vehicles for genetic medicines, further expanding the potential reach of Beam’s genetic medicines into new target tissues and diseases. “Since our founding, Beam’s strategy has been to establish the leading, fully integrated platform for precision genetic medicine,” said John Evans, chief executive officer of Beam. “We believe that the innovative scientists and technology at GuideTx will